Lv41
620 积分 2022-05-11 加入
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
7个月前
已完结
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
8个月前
已完结
Targeting KRAS in cancer
8个月前
已完结
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers
8个月前
已完结
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
9个月前
已完结
Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
9个月前
已完结
Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma
10个月前
已完结
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
1年前
已完结
Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma
1年前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
1年前
已完结
皖公网安备34019202002308
